ArticleMolecular systems biology2019
Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks.
Article in Molecular systems biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 60 citations in OpenAlex.
- Dnmt1 mediates epigenetic restriction of invasive traits in clonal crayfish.Nature communications · 2026Article
- Concordant Shared Transcriptomic Signatures and Candidate Regulatory Features in Chronic Lymphocytic Leukemia and Multiple Myeloma.Oncology research · 2026Article
- Two distinct chromatin modules regulate proinflammatory gene expression.Nature cell biology · 2026Article
- The Chronic Lymphocytic Leukemia Epigenome: A Powerful and Stable Framework for Understanding Biological and Clinical Heterogeneity.Hematology/oncology clinics of North America · 2025Review
- Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities.International journal of molecular sciences · 2025Review
- Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia.Blood neoplasia · 2025Article
- Transiently increased coordination in gene regulation during cell phenotypic transitions.PRX life · 2024Article
- Article
- Multiple omics levels of chronic lymphocytic leukemia.Cell death discovery · 2024Review
- B-1 derived anti-Thy-1 B cells in old aged mice develop lymphoma/leukemia with high expression of CD11b and Hamp2 that different from TCL1 transgenic mice.Immunity & ageing : I & A · 2024Article
- Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis.Blood · 2023Article
- Nucleosome repositioning in chronic lymphocytic leukemia.Genome research · 2023Article
- Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.Nature communications · 2023Article
- Epigenetic signals that direct cell type-specific interferon beta response in mouse cells.Life science alliance · 2023Article
- Enhancing sensitivity and versatility of Tn5-based single cell omics.Frontiers in epigenetics and epigenomics · 2023Article
- Machine learning and multi-omics data in chronic lymphocytic leukemia: the future of precision medicine?Frontiers in genetics · 2023Review
- Early growth response 1 transcription factor is essential for the pathogenic properties of human endometriotic epithelial cells.Reproduction (Cambridge, England) · 2022Article
- Towards precision medicine in lymphoid malignancies.Journal of internal medicine · 2022Review
- B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells.Blood cancer journal · 2022Article
- A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 3 countries.
Funding
Abstract
In chronic lymphocytic leukemia (CLL), a diverse set of genetic mutations is embedded in a deregulated epigenetic landscape that drives cancerogenesis. To elucidate the role of aberrant chromatin features, we mapped DNA methylation, seven histone modifications, nucleosome positions, chromatin accessibility, binding of EBF1 and CTCF, as well as the transcriptome of B cells from CLL patients and healthy donors. A globally increased histone deacetylase activity was detected and half of the genome comprised transcriptionally downregulated partially DNA methylated domains demarcated by CTCF CLL samples displayed a H3K4me3 redistribution and nucleosome gain at promoters as well as changes of enhancer activity and enhancer linkage to target genes. A DNA binding motif analysis identified transcription factors that gained or lost binding in CLL at sites with aberrant chromatin features. These findings were integrated into a gene regulatory enhancer containing network enriched for B-cell receptor signaling pathway components. Our study predicts novel molecular links to targets of CLL therapies and provides a valuable resource for further studies on the epigenetic contribution to the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.